EDWARDS LIFESCIENCES CORP

Carvolix boosts leadership, secures €40 m capital, and advances its TAVIPILOT platform to CE and FDA filing, aiming to expand global heart‑tech adoption and improve patient outcomes.

Nasdaq 100 bullish trend, strong earnings & aggressive buybacks—yet antitrust scrutiny and US‑China tensions loom. Dive into insights that sharpen investor strategy.

Edwards Lifesciences’ recent executive share sales reveal routine portfolio moves, not a shift in strategy, as the company continues to boost transcatheter valve access, cost‑effective outcomes and global market growth.

Edwards Lifesciences insider trades reveal strong confidence and highlight its robust financials, value‑based care strategy, and market‑leading TAVR performance.

Edwards Lifesciences & Carvolix launch the SAF‑MD alliance, boosting AI‑powered heart‑valve tech, local production in Saudi Arabia, and global cardiovascular innovation.

Edwards Lifesciences insider trades show routine option use & Rule 144 sales; reveals governance, liquidity, and growth strategy insights.

Edwards Lifesciences insider trades reveal executive confidence as the company drives high‑margin TAVR growth, value‑based pricing, and global expansion.

Edwards Lifesciences boosts its 2026 outlook after acquiring Autus Valve Technologies, adding high‑growth mitral and tricuspid products to its TAVR‑heavy portfolio and projecting 12% revenue growth and 18% EBITDA lift—while navigating regulatory, re…

Edwards Lifesciences insider trading filings reveal executive confidence and disciplined equity‑compensation compliance, offering investors insight into strategic liquidity and long‑term growth.

Edwards Lifesciences insider filings show routine COO equity trades—options, sales, Rule 144 compliance—highlighting typical medical‑device executive liquidity and transparency.